z-logo
Premium
Expression and Agonist‐Induced Down‐Regulation of mRNAs of m2‐ and m3‐Muscarinic Acetylcholine Receptors in Cultured Cerebellar Granule Cells
Author(s) -
Fukamauchi Fumihiko,
Hough Christopher,
Chuang DeMaw
Publication year - 1991
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.1991.tb08210.x
Subject(s) - muscarinic acetylcholine receptor , carbachol , pirenzepine , agonist , muscarinic acetylcholine receptor m2 , northern blot , endocrinology , biology , medicine , muscarinic acetylcholine receptor m1 , acetylcholine receptor , muscarinic acetylcholine receptor m3 , muscarinic agonist , acetylcholine , receptor , muscarinic acetylcholine receptor m4 , atropine , messenger rna , stimulation , microbiology and biotechnology , biochemistry , gene
The regulation and expression of muscarinic acetylcholine receptor (mAChR) mRNA was studied in cultured cerebellar granule cells using Northern blot hybridization. mRNA species for m2‐ and m3‐mAChRs but not ml‐ and m4‐mAChRs were detected in these cells. The expression of mRNAs of both m2‐ and m3‐mAChRs reached a maximum on the tenth day in culture but their expression patterns differed. Treatment of cerebellar granule cells after 8 days in culture with 100 μ M carbachol led to differential down‐regulation of the mRNA species of both mAChR subtypes present. Muscarinic receptor antagonists, atropine (1 μ M ) and pirenzepine (10 μ M ), prevented carbachol‐induced m3‐mAChR mRNA down‐regulation observed at 8 h. However, exposure to either atropine or pirenzepine alone for 8 h led to a significant up‐regulation of m3‐mAChR mRNA. Thus, the mRNA species for both m2‐ and m3‐mAChR subtypes are differentially expressed in culture and down‐regulated by agonist stimulation. The loss of these mRNA species may play a role in the down‐regulation of mAChR binding sites that occurs after desensitization.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here